PMID- 30848445
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20200309
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
VI  - 188
IP  - 4
DP  - 2019 Nov
TI  - Deep vein thrombosis during long-term surveillance of patients with liver 
      transplantation.
PG  - 1191-1193
LID - 10.1007/s11845-019-01998-6 [doi]
AB  - BACKGROUND: In the European Liver Transplant Registry, there are 137,863 liver 
      transplantations recorded. Forty-one percent of patients survived 20 years after 
      liver transplantation in the European countries. From 1988, when the US database 
      for liver transplantation was created, to 2006, there are more than 56,000 liver 
      transplants. Almost 80% of the liver transplant recipients survived 5 years after 
      transplantation. The incidence of deep vein thrombosis (DVT) in the European 
      population is 70-140/100.000 person-years. Cancer, paresis, immobilization, 
      thrombophilia, inflammatory bowel disease, replacement hormonal or contraceptive 
      therapies are associated with an increased risk of occurrence DVT or 
      complications. The incidence of DVT in long-term surveillance of liver transplant 
      recipients is unknown. Immunosuppressive therapy, thrombophilia abnormalities, 
      hepatitis C and hepatocellular carcinoma recurrence, renal insufficiency, 
      malignant tumours, obesity and diabetes were associated with DVT in long-term 
      post-liver transplantation. The reported maximum time between liver 
      transplantation and DVT was 210 days. AIM: The aim of the study is to update 
      existing data in the literature regarding the occurrence and management of deep 
      vein thrombosis in liver transplant patients over the long-term surveillence 
      period. CONCLUSIONS: There are no specific guideline recommendations regarding 
      acute DVT treatment in long-term surveillance after liver transplantation. Low 
      molecular weight heparin (LMWH), unfractionated heparin (UFH) and vitamin K 
      antagonist (VKA) are the anticoagulants used in specific complications 
      post-transplantation. The safety and the efficacy of direct anticoagulants in 
      liver transplantation recipients need to be assessed in future trials. Given that 
      long-term survival of liver transplantation is much improved, complications 
      associated with transplantation and ageing require appropriate cardiovascular 
      guidelines.
FAU - Balaceanu, Alice
AU  - Balaceanu A
AUID- ORCID: 0000-0003-0441-3905
AD  - Internal Medicine Department, "Sf. Ioan" Clinical Emergency Hospital, "Carol 
      Davila" University of Medicine and Pharmacy, Sos. Vitan-Barzesti nr. 13, 
      Bucharest, Romania. alicebalaceanu@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190308
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*administration & dosage
MH  - Europe
MH  - Heparin/administration & dosage
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse effects
MH  - Humans
MH  - Liver Transplantation/*statistics & numerical data
MH  - Thrombophilia/epidemiology
MH  - Venous Thrombosis/*epidemiology
OTO - NOTNLM
OT  - Deep vein thrombosis
OT  - Liver transplantation
OT  - Post-transplant long-term
EDAT- 2019/03/09 06:00
MHDA- 2020/01/14 06:00
CRDT- 2019/03/09 06:00
PHST- 2018/12/09 00:00 [received]
PHST- 2019/02/27 00:00 [accepted]
PHST- 2019/03/09 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
PHST- 2019/03/09 06:00 [entrez]
AID - 10.1007/s11845-019-01998-6 [pii]
AID - 10.1007/s11845-019-01998-6 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2019 Nov;188(4):1191-1193. doi: 10.1007/s11845-019-01998-6. Epub 
      2019 Mar 8.